Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Michael Y. He"'
Autor:
Victoria Shelton, Rajesh Detroja, Ting Liu, Keren Isaev, Anjali Silva, Verena Passerini, Mehran Bakhtiari, Lourdes Calvente, Michael Hong, Michael Y. He, Saloni Modi, Samantha A. Hershenfeld, Maja Ludvigsen, Charlotte Madsen, Stephen Hamilton-Dutoit, Francesco Annibale d’Amore, Marianne Brodtkorb, Nathalie A. Johnson, Tara Baetz, David LeBrun, Josh W. D. Tobin, Maher K. Gandhi, Andrew J. Mungall, Wei Xu, Susana Ben-Neriah, Christian Steidl, Jan Delabie, Rosemarie Tremblay-LeMay, Opeyemi Jegede, Oliver Weigert, Brad Kahl, Andrew M. Evens, Robert Kridel
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes in 713 pre-treatm
Externí odkaz:
https://doaj.org/article/34d7cb757e0c4fbe916aa9cea2b4742d
Autor:
Michael Y. He, Michael M. Halford, Ruofei Liu, James P. Roy, Zoe L. Grant, Leigh Coultas, Niko Thio, Omer Gilan, Yih-Chih Chan, Mark A. Dawson, Marc G. Achen, Steven A. Stacker
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
Through three-dimensional CRISPR screening, He et al. report that functional inhibition of BET family of proteins BRD2/3/4 shows mitigating effects on blood endothelial cell (EC) survival and/or proliferation upon VEGFA blockade. An interaction betwe
Externí odkaz:
https://doaj.org/article/0a802170899b49c7b97c4550e22321e7
Autor:
Robert Kridel, Christian Steidl, David W. Scott, Merrill Boyle, Lauren C. Chong, Elizabeth A. Chavez, Rodger E. Tiedemann, Housheng Hansen He, Gilbert G. Privé, Maria C. Xu, Anjali Silva, Jesse Joynt, Michael Y. He, Tracy Lackraj, Mehran Bakhtiari, Keren Isaev, Sharon Yoon, Kit I. Tong
Results from CRISPR/Cas9 knockout screen in SU-DHL-4 cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7d4c08af6454c34ea2a2834ec2eb5ad3
https://doi.org/10.1158/1078-0432.22481609.v1
https://doi.org/10.1158/1078-0432.22481609.v1
Autor:
Robert Kridel, Christian Steidl, David W. Scott, Merrill Boyle, Lauren C. Chong, Elizabeth A. Chavez, Rodger E. Tiedemann, Housheng Hansen He, Gilbert G. Privé, Maria C. Xu, Anjali Silva, Jesse Joynt, Michael Y. He, Tracy Lackraj, Mehran Bakhtiari, Keren Isaev, Sharon Yoon, Kit I. Tong
Purpose:The efficacy of EZH2 inhibition has been modest in the initial clinical exploration of diffuse large B-cell lymphoma (DLBCL), yet EZH2 inhibitors are well tolerated. Herein, we aimed to uncover genetic and pharmacologic opportunities to enhan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61ea15c004b3550df88ad0d2b64db44c
https://doi.org/10.1158/1078-0432.c.6530741.v1
https://doi.org/10.1158/1078-0432.c.6530741.v1
Autor:
Robert Kridel, Christian Steidl, David W. Scott, Merrill Boyle, Lauren C. Chong, Elizabeth A. Chavez, Rodger E. Tiedemann, Housheng Hansen He, Gilbert G. Privé, Maria C. Xu, Anjali Silva, Jesse Joynt, Michael Y. He, Tracy Lackraj, Mehran Bakhtiari, Keren Isaev, Sharon Yoon, Kit I. Tong
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dedf107ae003a03ebdc635ba308d6ab9
https://doi.org/10.1158/1078-0432.22481612.v1
https://doi.org/10.1158/1078-0432.22481612.v1
Autor:
Michael Y. He, Kit I. Tong, Mehran Bakhtiari, Ryder Whittaker Hawkins, Ting Liu, Yong Zeng, Noorhan Ghanem, Housheng Hansen He, Robert Kridel
Publikováno v:
Cancer Research. 83:1757-1757
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma and represents a highly heterogeneous and aggressive disease. Up to 40% of all DLBCL patients experience treatment failure after the standard immunochemotherapy
Autor:
Michael Y. He, Robert Kridel
Publikováno v:
Leukemia. 35:2151-2165
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents the most common subtype of lymphoma. Although 60-70% of all patients can be cured by the current standard of care in the frontline setting, the majority of the rem
Autor:
Marc G. Achen, Niko Thio, Omer Gilan, Michael Y. He, Leigh Coultas, Michael M. Halford, Zoe L. Grant, Steven A. Stacker, Yih-Chih Chan, Ruofei Liu, James P. Roy, Mark A. Dawson
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-15 (2021)
Communications Biology
Communications Biology
Angiogenesis underlies development, physiology and pathogenesis of cancer, eye and cardiovascular diseases. Inhibiting aberrant angiogenesis using anti-angiogenic therapy (AAT) has been successful in the clinical treatment of cancer and eye diseases.
Autor:
Michael Y, He, Robert, Kridel
Publikováno v:
Leukemia. 35(8)
Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease and represents the most common subtype of lymphoma. Although 60-70% of all patients can be cured by the current standard of care in the frontline setting, the majority of the rem
Autor:
Elizabeth A. Chavez, Maria C. Xu, Sharon Yoon, Lauren C. Chong, Jesse Joynt, Keren Isaev, Merrill Boyle, Tracy Lackraj, Gilbert G. Privé, Christian Steidl, Housheng Hansen He, David Scott, Rodger E. Tiedemann, Kit I. Tong, Anjali Silva, Michael Y. He, Robert Kridel, Mehran Bakhtiari
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(19)
Purpose:The efficacy of EZH2 inhibition has been modest in the initial clinical exploration of diffuse large B-cell lymphoma (DLBCL), yet EZH2 inhibitors are well tolerated. Herein, we aimed to uncover genetic and pharmacologic opportunities to enhan